Predictors of surgical quality for retroperitoneal sarcoma: Volume matters.

BACKGROUND AND OBJECTIVES: The volume-outcome relationship is well recognized. We sought to investigate this relationship in retroperitoneal sarcoma (RPS) surgery. METHODS: Non-metastatic RPS cases from 2004 to 2014 in the National Cancer Database were analyzed. Hospitals in the top 10th percentile for volume were defined as high-volume. Outcomes were selected a priori based on their known prognostic significance, including surgery use, R0/R1 resection, and R0 resection. Volume-outcome associations were assessed by univariate and multivariable analyses. RESULTS: Of 3141 RPS cases identified, 70.0% were managed surgically. Of these, 93.0% were R0/R1 resections, and 67.6% were R0 resections. Surgical management, R0/R1 resection, and R0 resection were each associated with improved overall survival (P < 0.001). Hospital volume was an independent predictor of surgical management, R0 resection, and R0/R1 resection. Patients treated at high-volume centers had 1.9-fold higher odds of undergoing surgical management (P < 0.001), 2.5-fold higher odds of receiving a R0/R1 resection (P = 0.026), and 1.8-fold higher odds of an R0 resection (P < 0.001). Academic setting predicted use of surgical management (P < 0.001) and R0/R1 resection (P = 0.015) but not R0 resection (P = 0.882). CONCLUSIONS: High-volume hospitals are significantly associated with surgery use and improved surgical outcomes. Consideration should be given to further centralization of RPS care.

Changes in sexual functioning in women after neuromodulation for voiding dysfunction.

INTRODUCTION: Sacral neuromodulation is a well-established treatment for urinary and bowel disorders with potential use for other disorders such as sexual dysfunction. AIM: To evaluate changes in sexual functioning in women undergoing neuromodulation for voiding symptoms. METHODS: Patients enrolled in our prospective, observational neuromodulation database study were evaluated. Data were collected from medical records, and patient-completed Female Sexual Function Index (FSFI) and Interstitial Cystitis Symptom-Problem Indices (ICSI-PI) at baseline, 3, 6, and 12 months post-implant. Patients rated overall change in sexual functioning on scaled global response assessments (GRA) at 3, 6, and 12 months post-implant. We grouped women by baseline FSFI scores: less (score<26) and more sexually functional (score≥26). Data were analyzed with Pearson's Chi-square or Fisher's Exact test and repeated measures. MAIN OUTCOMES MEASURES: Changes in FSFI and ICSI-PI scores in women grouped by baseline FSFI score<26 and ≥26. RESULTS: Of 167 women evaluated, FSFI scores improved overall from preimplant (mean 13.5±8.5) to 12 months (N=72; mean 15.9±8.9, P=0.004). At baseline and each follow-up point, ICSI-PI scores were similar between groups and improved through time. For patients in the FSFI<26 group there was improvement from baseline to 12-month scores (N=63; 11.9±6.9 to 14.8±8.7; P=0.0006). Improved FSFI domains included desire, orgasm, satisfaction, and pain. Furthermore, of the 74 subjects in this group not sexually active at baseline, 10 became sexually active during follow-up. In the FSFI≥26 group there was slight but statistically significant decline in mean scores between baseline and 12 months (N=9; 27.4±1.1 to 24.5±3.4; P=0.0302); however one had become sexually inactive. A significant decrease was seen in the satisfaction domain. CONCLUSIONS: Many factors affect sexual functioning in women; however sexual function may improve along with urinary symptoms after neuromodulation.

Improved surgical outcomes following radical cystectomy at high-volume centers influence overall survival.

OBJECTIVES: Positive surgical margins (PSM) and lymph node yield (LNY) following radical cystectomy (RC) for urothelial carcinoma of the bladder affect survival. Variations in PSM or LNY at different care facilities are poorly described. We evaluated the relationship between hospital surgical volume and academic hospital status with these surgical outcomes and overall survival (OS). METHODS AND MATERIALS: Patients with nonmetastatic urothelial carcinoma of the bladder who underwent RC were identified from the National Cancer Database (2004-2013). Treatment centers were categorized as academic (ACC) and community cancer centers (CCC). Logistic regression was used to identify factors associated with PSM status and LNY, and a multivariate Cox proportional hazards model was used to determine factors associated with OS. RESULTS: In our cohort, 39,274 patients underwent RC. A lower proportion of PSMs (10% vs.12%; P<0.001) and higher median LNY (14 vs. 8, P<0.001) was observed at ACCs compared to CCCs. On logistic regression, there were lower odds of PSM (OR = 0.89, 95% CI: 0.81-0.97) and higher odds of LNY ≥ 10 nodes (OR = 1.84, 95% CI: 1.74-1.96) among patients at ACCs compared to CCCs. Cox proportional hazards analysis demonstrated benefit to OS at high-volume centers (HR = 0.91, 95% CI: 0.87-0.95) but not based on ACC designation. The OS advantage at high-volume centers is attenuated (HR = 0.95, 95% CI: 0.91-0.99) by PSM status and LNY. CONCLUSIONS: ACCs demonstrate improved surgical outcomes following RC, and a survival advantage attributable to high surgical volume is identified. Centralization of care may lead to improved outcomes in this lethal malignancy.